• Search
  • Helpdesk
  • Sales contact
Get your demo

Oncology

Advancing oncology research: the crucial role of patient-reported outcomes in patient-centric, decentralised clinical trials

Oncology
Despite recent estimates showing a 7.1% enrollment rate in cancer treatment trials, surpassing historical figures of less than 5%, the challenges of recruiting and retaining patients in oncology clinical trials...

How Kayentis Delivered eCOA Go-Live in Just 5 Weeks for a Phase 1 Oncology Study

OncologySet up
A PHASE 1 ONCOLOGY STUDY IN ADULTS WITH METASTATIC BONE PAINKayentis delivered the electronic solution for daily capture of:an NRS-based...

ePRO in early phase oncology trials: A revolution on the horizon

Oncology
While the integration of Patient-Reported Outcomes (PROs) into phase IIb and III clinical trials has become increasingly widespread in the...

Patient-Reported Outcomes in early-phase oncology clinical trials
A Stepping Stone to a Patient-Centered Drug Development

Oncology
In phase I clinical trials, the recommended phase II dose (RP2D) is usually set at or near the maximum tolerated...

Rethinking Phase 1 Oncology Trials with Electronic Patient-Reported Outcomes

OncologyPRO
Go back ● On-demand The primary aim of Phase 1 oncology clinical trials is to determine the safety of a...

If Patients Want A Better Quality Of Life, Why Isn’t That A Focus For Pharma?

OncologyPatient engagement
A conversation with Frédéric Fiteni, Ph.D., medical oncologist and oncology PRO specialist, University Hospital of Nîmes, and, member of Kayentis Scientific...

Collecting PRO data in leukemia clinical research: the only way to meaningfully improve patients’ quality of life

Oncology
The prevalence of leukemia is increasing worldwide. Chronic Myeloid Leukemia (CML) patients benefit from recently improved care but receive prolonged,...

Collecting PRO data in cancer trials: bringing the patient perspective in oncology clinical research

Oncology
As one of the biggest research area, oncology remains the focus of the clinical trials pipeline, comprising 44% of the...

Direct insights from cancer patients: How they help us understand disease burden and the need for an individualized approach

OncologyPatients insights
Cultural differences and individual preferences have a significant impact on healthcare and clinical trial experience. Solutions exist in attempt to...

Mitigating the risks of long-term oncology eCOA clinical trials

Oncology
Long study duration can have a negative impact on patient complianceAs for any clinical trial, poor compliance in oncology studies...

Addressing the specific complexities of oncology eCOA clinical trials

Oncology
The oncology research pathway is paved with numerous challenges, and oncology clinical trials have one of the lowest success rates....

Oncology Case Study

Oncology
Oncology studies present specific challenges that generate complex eCOA build and management: complex study design, frequent amendments, and long study...

eCOA solutions in oncology: how to avoid common pitfalls and ensure the success of long-term studies?

Oncology
Among numerous clinical study procedures, capturing patients reported outcomes can bring its own set of challenges and, if not well...

eCOA challenges of long term studies

OncologyProject management
How to anticipate eCOA complexities in multi-year studies & develop best practice to support sites? Using eCOA solutions can bring...

Kayentis supports the 1st personalized immunotherapy treatment approved by both FDA & EMA

Oncology
Acute Lymphoblastic or Lymphoid Leukemia (ALL) is a cancer of the lymphocytes that can result in serious complications such as...
Follow us on social media
Subscribe to our newsletter
You may also like

Turning neuroscience trial complexity into meaningful clinical evidence with eCOA

From passive sensors to patient voice: the value of integrating...

Advancing oncology research: the crucial role of patient-reported outcomes in...

6 Best Practices for Accelerating eCOA Study Start-Up Timelines

How Kayentis Delivered eCOA Go-Live in Just 5 Weeks for...

Turning endpoint noise into reliable CNS trial data

About the author
Picture of Marc Chaperon

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.
Turning endpoint noise into reliable CNS trial data
Discover how lifecycle rater training and eCOA work together to improve endpoint quality
  • Download the white paper